Cargando…

Plasticity of melanoma and EMT-TF reprogramming

Detalles Bibliográficos
Autores principales:	Tulchinsky, Eugene, Pringle, J. Howard, Caramel, Julie, Ansieau, Stéphane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2013
Materias:	Editorial Material
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960181/ https://www.ncbi.nlm.nih.gov/pubmed/24369126

Ejemplares similares

EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment
por: Tang, Yaqi, et al.
Publicado: (2020)

EMT or EMT-Promoting Transcription Factors, Where to Focus the Light?
por: Ansieau, Stéphane, et al.
Publicado: (2014)

Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma
por: Benboubker, Valentin, et al.
Publicado: (2022)

EMT/MET plasticity in cancer and Go-or-Grow decisions in quiescence: the two sides of the same coin?
por: Akhmetkaliyev, Azamat, et al.
Publicado: (2023)

ZEB1‐mediated melanoma cell plasticity enhances resistance to MAPK inhibitors
por: Richard, Geoffrey, et al.
Publicado: (2016)

Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogramed primary prostate cancer cells.
por: Pollock, Claire B, et al.
Publicado: (2014)

Intrinsic flexibility of porous materials; theory, modelling and the flexibility window of the EMT zeolite framework
por: Fletcher, Rachel E., et al.
Publicado: (2015)

Senescence versus apoptosis in chemotherapy
por: Ansieau, Stéphane, et al.
Publicado: (2015)

ELF3 is an antagonist of oncogenic-signalling-induced expression of EMT-TF ZEB1
por: Liu, D, et al.
Publicado: (2018)

EMT in immuno-resistance
por: Terry, Stéphane, et al.
Publicado: (2015)

Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date
por: Boespflug, Amélie, et al.
Publicado: (2017)

Melanoma Cellular Plasticity
por: Novak, Daniel, et al.
Publicado: (2022)

Cellular Reprogramming—A Model for Melanoma Cellular Plasticity
por: Granados, Karol, et al.
Publicado: (2020)

Mapping pure plastic strains against locally applied stress: Revealing toughening plasticity
por: Edwards, Thomas E. J., et al.
Publicado: (2022)

Invasive leader cells: metastatic oncotarget
por: Cheung, Kevin J., et al.
Publicado: (2014)

Snail Family Members Unequally Trigger EMT and Thereby Differ in Their Ability to Promote the Neoplastic Transformation of Mammary Epithelial Cells
por: Gras, Baptiste, et al.
Publicado: (2014)

IRAK1: oncotarget in MDS and AML
por: Beverly, Levi J., et al.
Publicado: (2014)

Current developments in toxicology
por: Stewart, J. D., et al.
Publicado: (2012)

NMI and EMT
por: Samant, Rajeev S., et al.
Publicado: (2014)

Extracellular Acidosis Differentially Regulates Estrogen Receptor β-Dependent EMT Reprogramming in Female and Male Melanoma Cells
por: Peppicelli, Silvia, et al.
Publicado: (2022)

Radiation hardness of lead glasses TF1 and TF101
por: Kobayashi, M, et al.
Publicado: (1993)

Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma
por: Falletta, Paola, et al.
Publicado: (2017)

The Heterodimeric TWIST1-E12 Complex Drives the Oncogenic Potential of TWIST1 in Human Mammary Epithelial Cells()
por: Jacqueroud, Laurent, et al.
Publicado: (2016)

Intestinal Epithelial Cells Adapt to Chronic Inflammation through Partial Genetic Reprogramming
por: Collin, Guillaume, et al.
Publicado: (2023)

Role of Metabolic Reprogramming in Epithelial–Mesenchymal Transition (EMT)
por: Kang, Hyunkoo, et al.
Publicado: (2019)

In vivo selection of tumor-specific antibodies
por: Sánchez-Martín, David, et al.
Publicado: (2013)

Estrogen response in luminal breast cancer
por: Rangel, Leticia B. A., et al.
Publicado: (2013)

IκBα beyond the NF-kB dogma
por: Mulero, Maria Carmen, et al.
Publicado: (2013)

Cytokine-induced ‘bystander’ senescence in DDR and immuno-surveillance
por: Hodny, Zdenek, et al.
Publicado: (2013)

Ribosomes: the future of targeted therapies?
por: Marcel, Virginie, et al.
Publicado: (2013)

CDK6 and p16(INK4A) in lymphoid malignancies
por: Kollmann, Karoline, et al.
Publicado: (2013)

Targeting IL-11 signaling in colon cancer
por: Ernst, Matthias, et al.
Publicado: (2013)

Hexokinase 2 as oncotarget
por: Patra, Krushna C., et al.
Publicado: (2013)

MicroRNAs as regulators of tumor-associated stromal cells
por: Ell, Brian, et al.
Publicado: (2013)

MYC and MiR: vicious circle
por: Zhao, Xiaohong, et al.
Publicado: (2013)

Wip1 and ATM in tumor evolution: role for BRCA1
por: Filipponi, Doria, et al.
Publicado: (2013)

DNp73: oncotarget in invasion and metastasis
por: Pützer, Brigitte M.
Publicado: (2013)

Breaking Bad: how does a neuronal protein cause neuroendocrine cancer?
por: Pozo, Karine, et al.
Publicado: (2013)

Spherical nucleic acids for precision medicine
por: Mirkin, Chad A., et al.
Publicado: (2013)

Impact of Wikipedia on citation trends
por: Marashi, Sayed-Amir, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_it83pr7srpspc94l775dtdndco